

WEST Search History

[Hide Items](#) [Restore](#) [Clear](#) [Cancel](#)

DATE: Monday, June 20, 2005

| <u>Hide?</u> | <u>Set Name</u> | <u>Query</u> | <u>Hit Count</u> |
|---|-----------------|---|------------------|
| <i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i> | | | |
| <input type="checkbox"/> | L14 | L13 and L10 | 18 |
| <input type="checkbox"/> | L13 | L7 and incretin hormone | 52 |
| <input type="checkbox"/> | L12 | L10 and L9 | 2 |
| <input type="checkbox"/> | L11 | L10 and L9 or L8 | 11 |
| <input type="checkbox"/> | L10 | exendin near3 impaired glucose tolerance or IGT | 6673 |
| <input type="checkbox"/> | L9 | L8 and GLP-1 or 7-37 Or 7-36 amide | 3 |
| <input type="checkbox"/> | L8 | L7 and L5 or L6 | 11 |
| <input type="checkbox"/> | L7 | L4 and exendin or exendin 3 or exendin 4 | 442 |
| <input type="checkbox"/> | L6 | L4 and receptor binding compound\$ | 11 |
| <input type="checkbox"/> | L5 | L4 and receptor binding compound\$ | 11 |
| <input type="checkbox"/> | L4 | L3 and non-insulin dependent diabetes mellitus or NIDDM or type II diabetes | 9515 |
| <input type="checkbox"/> | L3 | L2 and treat\$\$\$ or ameliorat\$\$\$ or prevent\$\$\$ or therapeut\$\$\$ | 5626153 |
| <input type="checkbox"/> | L2 | L1 and impaired glucose tolernce or IGT | 6673 |
| <input type="checkbox"/> | L1 | glucagon like peptide 1 or GLP 1 | 2073 |

END OF SEARCH HISTORY

Refine Search

Search Results -

| Terms | Documents |
|-------------|-----------|
| L13 and L10 | 18 |

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

| | |
|-----|----------------------|
| L14 | Refine Search |
|-----|----------------------|

Search History

DATE: Monday, June 20, 2005 [Printable Copy](#) [Create Case](#)

| <u>Set</u> <u>Name</u> | <u>Query</u> | <u>Hit Count</u> | <u>Set</u> <u>Name</u> |
|---|---|------------------|---------------------------|
| side by side | | | result set |
| <u>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</u> | | | |
| <u>L14</u> | L13 and L10 | 18 | <u>L14</u> |
| <u>L13</u> | L7 and incretin hormone | 52 | <u>L13</u> |
| <u>L12</u> | L10 and L9 | 2 | <u>L12</u> |
| <u>L11</u> | L10 and L9 or L8 | 11 | <u>L11</u> |
| <u>L10</u> | exendin near3 impaired glucose tolerance or IGT | 6673 | <u>L10</u> |
| <u>L9</u> | L8 and GLP-1 or 7-37 Or 7-36 amide | 3 | <u>L9</u> |
| <u>L8</u> | L7 and L5 or L6 | 11 | <u>L8</u> |
| <u>L7</u> | L4 and exendin or exendin 3 or exendin 4 | 442 | <u>L7</u> |
| <u>L6</u> | L4 and receptor binding compound\$ | 11 | <u>L6</u> |
| <u>L5</u> | L4 and receptor binding compound\$ | 11 | <u>L5</u> |
| <u>L4</u> | L3 and non-insulin dependent diabetes mellitus or NIDDM or type II diabetes | 9515 | <u>L4</u> |
| <u>L3</u> | L2 and treat\$\$\$ or ameliorat\$\$\$ or prevent\$\$\$ or therapeut\$\$\$ | 5626153 | <u>L3</u> |

L2 L1 and impaired glucose tolerance or IGT
L1 glucagon like peptide 1 or GLP 1

6673 L2
2073 L1

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 11 of 11 returned.**

1. [20050042691](#). 28 Jun 04. 24 Feb 05. Methods for identifying active compounds. Parrow, Vendela, et al. 435/7.2; G01N033/53 G01N033/567.

2. [20050009127](#). 02 Aug 04. 13 Jan 05. GLP-1 as a diagnostic test to determine beta-cell function and the presence of the condition of IGT and type-II diabetes. Holst, J.J., et al. 435/14; 514/12 C12Q001/54 A61K038/17.

3. [20030091507](#). 26 Oct 01. 15 May 03. GLP-1 as a diagnostic test to determine beta-cell function and the presence of the condition of IGT and type-II diabetes. Holst, J. J., et al. 424/9.2; 514/12 A61K049/00 A61K038/28.

4. [20030087306](#). 13 Dec 01. 08 May 03. Methods for identifying novel multimeric agents that modulate receptors. Christensen, Burton G., et al. 435/7.1; 436/518 G01N033/53 G01N033/543.

5. [20030032588](#). 02 May 01. 13 Feb 03. Glucagon antagonists. Marshall, William S., et al. 514/12; A61K038/16.

6. [6768024](#). 04 Aug 00; 27 Jul 04. Triamine derivative melanocortin receptor ligands and methods of using same. Watson-Straughan; Karen J., et al. 564/367; 544/107 544/162 546/277.4 546/300 548/340.1 549/65 564/229 564/230 564/237. C07C211/00.

7. [6677136](#). 02 May 01; 13 Jan 04. Glucagon antagonists. Marshall; William S., et al. 435/69.1; C12P021/06.

8. [6482844](#). 06 Apr 01; 19 Nov 02. 1-benzylimidazole derivatives. He; Xiao-Shu, et al. 514/399; 548/338.1. A61K031/415 C07D233/54.

9. [6479498](#). 09 Nov 01; 12 Nov 02. Sodium channel drugs and uses. Marquess; Daniel, et al. 514/256; 514/275 544/325 544/326 544/327 544/329. C07D239/42 C07D239/48 A61K031/505.

10. [6420354](#). 08 Dec 99; 16 Jul 02. Sodium channel drugs and uses. Marquess; Daniel, et al. 514/183; 514/357 514/438 514/651 540/470 546/334 549/75 564/353. C07D245/02 C07D211/70 C07D333/12 A61K031/33 A61K031/44.

11. [6007998](#). 21 Apr 97; 28 Dec 99. Leptin assay. Rosenblum; Charles I., et al. 435/7.1; 435/7.2 435/7.21 435/7.8. G01N033/53 G01N033/50.

[Generate Collection](#)[Print](#)

| Terms | Documents |
|-----------------|-----------|
| L7 and L5 or L6 | 11 |

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 3 of 3 returned.**

1. 20050009127. 02 Aug 04. 13 Jan 05. GLP-1 as a diagnostic test to determine beta-cell function and the presence of the condition of IGT and type-II diabetes. Holst, J.J., et al. 435/14; 514/12 C12Q001/54 A61K038/17.

2. 20030091507. 26 Oct 01. 15 May 03. GLP-1 as a diagnostic test to determine beta-cell function and the presence of the condition of IGT and type-II diabetes. Holst, J. J., et al. 424/9.2; 514/12 A61K049/00 A61K038/28.

3. 6482844. 06 Apr 01; 19 Nov 02. 1-benzylimidazole derivatives. He; Xiao-Shu, et al. 514/399; 548/338.1. A61K031/415 C07D233/54.

[Generate Collection](#)[Print](#)

| Terms | Documents |
|------------------------------------|-----------|
| L8 and GLP-1 or 7-37 Or 7-36 amide | 3 |

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 2 of 2 returned.**

1. 20050009127. 02 Aug 04. 13 Jan 05. GLP-1 as a diagnostic test to determine beta-cell function and the presence of the condition of IGT and type-II diabetes. Holst, J.J., et al. 435/14; 514/12 C12Q001/54 A61K038/17.

2. 20030091507. 26 Oct 01. 15 May 03. GLP-1 as a diagnostic test to determine beta-cell function and the presence of the condition of IGT and type-II diabetes. Holst, J. J., et al. 424/9.2; 514/12 A61K049/00 A61K038/28.

[Generate Collection](#)[Print](#)

| Terms | Documents |
|------------|-----------|
| L10 and L9 | 2 |

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

Search Results - Record(s) 1 through 18 of 18 returned.

1. [20050042614](#). 15 Oct 04. 24 Feb 05. Methods to treat diabetes and related conditions based on polymorphisms in the tcf-1 gene. Hughes, Thomas Edward, et al. 435/6; C12Q001/68.

2. [20050009127](#). 02 Aug 04. 13 Jan 05. GLP-1 as a diagnostic test to determine beta-cell function and the presence of the condition of IGT and type-II diabetes. Holst, J.J., et al. 435/14; 514/12 C12Q001/54 A61K038/17.

3. [20040209866](#). 28 Apr 04. 21 Oct 04. 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders. Wang, Yamin, et al. 514/217.07; 514/227.8 514/234.2 514/253.04 514/300 544/127 544/362 544/60 546/122 C07D471/02 A61K031/55 A61K031/541 A61K031/5377 A61K031/496 A61K031/4745.

4. [20040157875](#). 10 Oct 03. 12 Aug 04. 1, 6-Naphthyridine derivatives and their use to treat diabetes and related disorders. Wang, Yamin, et al. 514/300; 544/126 544/362 544/60 546/122 C07D471/02 A61K031/4745.

5. [20040058870](#). 11 Jul 03. 25 Mar 04. Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonists and their pharmacological methods of use. Froland, Wayne A., et al. 514/12; 435/320.1 435/325 435/69.1 530/350 530/388.22 536/23.5 C07H021/04 C12P021/02 C12N005/06 C07K014/705 C07K016/28.

6. [20040014751](#). 23 Sep 02. 22 Jan 04. 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders. Wang, Yamin, et al. 514/227.8; 514/233.8 514/253.04 514/300 544/127 544/362 544/60 546/122 A61K031/541 A61K031/5377 A61K031/496 C07D471/02 A61K031/4745.

7. [20040002519](#). 21 Mar 03. 01 Jan 04. Combination of organic compounds. Damon, Robert Edson, et al. 514/342; 514/369 514/423 514/460 514/548 514/592 A61K031/4439 A61K031/426 A61K031/366 A61K031/401 A61K031/175 A61K031/225.

8. [20030199451](#). 20 May 03. 23 Oct 03. Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders. Mogensen, John Patrick, et al. 514/12; 514/357 514/408 514/419 514/469 514/567 514/570 A61K038/26 A61K031/44 A61K031/405 A61K031/40 A61K031/343 A61K031/192 A61K031/195.

9. [20030139434](#). 10 Oct 02. 24 Jul 03. Combinations comprising dipeptidylpeptidase-iv inhibitor. Balkan, Bork, et al. 514/275; 514/3 514/342 514/343 514/369 514/423 514/470 514/492 514/563 514/592 A61K038/28 A61K031/506 A61K031/4439 A61K031/426 A61K031/401 A61K031/365 A61K031/195 A61K031/28 A61K031/175.

10. [20030139429](#). 06 Sep 02. 24 Jul 03. Combinations. Cohen, David Saul. 514/263.22; A61K031/522.

11. [20030114469](#). 28 Aug 02. 19 Jun 03. Combinations. Cohen, David Saul. 514/263.22; A61K031/522.

12. [20030091507](#). 26 Oct 01. 15 May 03. GLP-1 as a diagnostic test to determine beta-cell

function and the presence of the condition of IGT and type-II diabetes. Holst, J. J., et al. 424/9.2; 514/12 A61K049/00 A61K038/28.

13. 20020193390. 20 Jun 02. 19 Dec 02. Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV. Villhauer, Edwin Bernard. 514/275; 514/343 514/423 544/330 546/279.1 548/152 548/537 A61K031/506 A61K031/4439 A61K031/426 A61K031/401 C07D43/02 C07D417/02.

14. 6900205. 23 Sep 02; 31 May 05. 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders. Wang; Yamin, et al. 514/235.2; 514/253.04 514/299 544/127 544/362 546/183. A61K0315375 C07D41314.

15. 6884579. 26 Oct 01; 26 Apr 05. GLP-1 as a diagnostic test to determine .beta.-cell function and the presence of the condition of IGT and type-II diabetes. Holst; Jens J., et al. 435/6;. C12Q00168.

16. 6677352. 23 Sep 02; 13 Jan 04. 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders. Wang; Yamin, et al. 514/300; 544/127 544/362 546/122 546/123. A61K031/435 C07D471/04.

17. 6432969. 12 Jun 01; 13 Aug 02. N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV. Villhauer; Edwin Bernard. 514/275; 514/256 514/343 514/423 544/332 546/208 546/279.1 548/540. C07D237/24 C07D403/06 C07D401/12 A61K031/50 A61P029/00.

18. 6344180. 15 Jun 99; 05 Feb 02. GLP-1 as a diagnostic test to determine .beta.-cell function and the presence of the condition of IGT and type II diabetes. Holst; J. J., et al. 424/9.1; 435/4 435/7.1. A61K049/00.

[Generate Collection](#)

[Print](#)

| Terms | Documents |
|-------------|-----------|
| L13 and L10 | 18 |

[Prev Page](#) [Next Page](#) [Go to Doc#](#)